OncoTartis

company

About

A private biotechnology company.

  • 1 - 10

Details

Last Funding Type
Series Unknown
Last Funding Money Raised
$6M
Industries
Biometrics,Biotechnology,Health Care,Medical
Founded date
Jan 1, 2011
Number Of Employee
1 - 10
Operating Status
Active

OncoTartis, Inc. is a private biotechnology company established in 2011. Company’s founding IP came from Prof. Andrei Gudkov’s laboratory at Roswell Park Cancer Institute (Buffalo, NY). OncoTartis develops a novel category of anti-cancer drugs directed against tissue-specific targets for a subset of cancers (breast, prostate, ovarian, melanoma and hematological malignancies). Its leading product OT-82 is a nicotinamide phosphoribosyltransferase (NAMPT) inhibitor being developed to treat Acute Myeloid Leukemia (AML). Investigational New Drug application (IND) will be submitted to FDA in the forth quarter of 2017.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
1
$6M
OncoTartis has raised a total of $6M in funding over 2 rounds. Their latest funding was raised on Dec 11, 2017 from a Series Unknown round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Dec 11, 2017 Series Unknown $6M 1 Pharmstandard International Detail

Investors

Number of Lead Investors
Number of Investors
1
1
OncoTartis is funded by 1 investors. Pharmstandard International are the most recent investors.
Investor Name Lead Investor Funding Round
Pharmstandard International Yes Series Unknown